Erasca Shares Plunge 48% Following Patient Death in Cancer Drug Trial

Shares of Erasca crashed nearly 50% on Tuesday, closing at $9.90, after the company disclosed a patient death linked to pneumonitis during its Phase 1 ERAS-0015 trial. The developer of RAS/MAPK pathway-driven cancer therapies saw trading volume surge to 51 million shares, representing a 709% increase over its three-month average of 6.3 million shares. While initial reports labeled the passing as treatment-related, some analysts and company management are challenging that conclusion. A J.P. Morgan analyst noted that the event appeared to be a one-off case rather than a broad drug-related concern, citing the patient's history of a prior lung procedure as a factor that may have increased vulnerability. Despite the current volatility, ERAS-0015 has reportedly delivered outcomes above benchmarks for both pancreatic and lung cancer patients. However, investors remain cautious, awaiting full trial results to determine if pneumonitis is a recurring safety issue. The broader market showed mixed results for biotechnology. While Erasca plummeted, peer Revolution Medicines closed up 10% at $144.83. In the wider market, the S&P 500 slipped 0.48% to 7,139, and the Nasdaq Composite lost 0.90% to finish at 24,664. Notably, Erasca's stock had risen sevenfold over the past year prior to this decline.